Ligant is target assessment-as-a-service for CAR-T biotech founders.

Every year, hundreds of domain-expert scientists — post-docs, principal investigators, translational researchers — identify a therapeutic target they believe could be the foundation of a category-defining cell therapy company. Most of them never find out whether they're right. The systematic evaluation that pharma R&D departments run in-house, and that consulting firms charge $50K–$250K to deliver over 8–16 weeks, is priced out of reach for the pre-funded founder. The free public databases — OpenTargets, DepMap, the Human Protein Atlas, Cell Surface Protein Atlas, ClinicalTrials.gov — provide the raw material but require weeks of manual integration to produce investor-grade evidence.

We built Ligant.ai to close that gap.

Our platform acts as a virtual Head of Target Assessment: a multi-agent AI system that queries 20+ authoritative biomedical databases in parallel, synthesizes the evidence across genetics, expression, safety, competition, and commercial viability, and produces a structured, citation-grounded dossier a founder can defend to investors.

Three principles are non-negotiable:

- Provenance-first. Every claim traces to a timestamped source query. No parametric guessing.
- Glass-box transparency. Every agent step, tool call, and confidence level is visible to the founder.
- Human decision gates. The platform presents the evidence. The founder decides — build, kill, or pivot.

We built Ligant for the scientist who already believes. Our job is to pressure-test that belief against every dimension that matters for company formation — honestly, including the evidence that might kill the thesis.

You know the biology. We help you prove the company.

ligant.ai

Ligant

Org chart

Teams

Offices

Ligant

Org chart

Teams

Offices

Related companies